Clinical and microbiological end points in the treatment of pneumonia

Abstract

The US Food and Drug Administration is reviewing its criteria for evaluating new antibiotics for the treatment of bacterial pneumonia. Although there are descriptions of hundreds of comparative studies of various antimicrobials, there is surprisingly little scientific literature on how the evaluations should be done. This brief contribution outlines areas for further consideration as new drugs are evaluated.